GE Aerospace stock jumps to a fresh 52-week high to start 2026, with earnings next in focus

GE Aerospace stock jumps to a fresh 52-week high to start 2026, with earnings next in focus

NEW YORK, Jan 3, 2026, 13:55 ET — Market closed

GE Aerospace shares (GE) jumped 4.13% on Friday, the first trading day of 2026, to close at $320.75. The stock traded between $308.66 and $320.98, and about 4.3 million shares changed hands, data showed. 1

The move pushed the jet-engine maker to a new 52-week high, topping its prior peak of $318.06 set on Dec. 26. GE also outpaced aerospace peers as U.S. stocks ended higher, with Honeywell up 0.4% and RTX gaining 2.1%. 2

Why it matters now: GE ended 2025 with an 83% rally, standing out even as trade and growth worries weighed on parts of the industrial sector. Bill Gunderson, president of Gunderson Capital Management, called GE a “blue-chip breakout” and wrote, “We remain long in our Premier Growth Portfolio.” 3

The fresh high extends momentum that investors have tied to GE’s engine output and its services-heavy model. In October, the company raised its 2025 guidance after reporting higher revenue, profit and free cash flow, citing robust demand and improved output, and it said services revenue rose while LEAP deliveries hit a quarterly record. 4

That services stream is the aftermarket — maintenance and spare parts sold after engines enter service — and it can hold up better than new-equipment sales when aircraft build rates wobble.

The stock’s sharp start to the year leaves investors sensitive to any data that shifts the rates outlook, which often steers sentiment on industrial shares.

Before the next session, traders will parse two U.S. inflation-and-jobs markers that can move Treasury yields and equity risk appetite. The Employment Situation report is due Jan. 9 and the CPI report is scheduled for Jan. 13. 5

GE Aerospace’s next company catalyst is close behind: it is scheduled to host its fourth-quarter 2025 earnings webcast on Jan. 22 at 7:30 a.m. EST, the company’s investor relations site shows. 6

Investors will look for updates on orders, engine delivery pace and free cash flow — a measure of cash left after capital spending — alongside any early signals on 2026 demand and margins.

The calendar also includes a cash return event: GE Aerospace’s board has declared a $0.36 per-share dividend payable on Jan. 26. 7

After Friday’s jump, chart watchers will focus on whether the stock can hold above the prior breakout area around $318, or whether profit-taking pulls it back toward the $308 level it closed 2025 near.

U.S. markets reopen Monday, with GE starting 2026 at a record level and a January lineup of macro and company events set to test how durable that move is.

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Nike stock today: NKE slips into 2026 as rates rise and investors brace for jobs data
Previous Story

Nike stock today: NKE slips into 2026 as rates rise and investors brace for jobs data

Why D-Wave Quantum (QBTS) stock jumped 8% — and what investors are watching next
Next Story

Why D-Wave Quantum (QBTS) stock jumped 8% — and what investors are watching next

Go toTop